2K35

Hydramacin-1: Structure and antibacterial activity of a peptide from the basal metazoan Hydra

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	3D HNCA	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298
2	3D HNCO	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298
3	3D H(CCO)NH	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298
4	3D C(CO)NH	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298
5	3D HCACO	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298
6	3D CBCA(CO)NH	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298
7	3D HNCACB	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298
8	3D 1H-15N NOESY	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298
9	3D 1H-15N TOCSY	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298
10	3D 1H-13C NOESY	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298
11	3D HCCH-TOCSY	1.0 mM [U-100% 13C; U-100% 15N] hydramacin-1	93% H2O/7% D2O	0.050	5.7	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	DRX	600

NMR Refinement
Method	Details	Software
simulated annealing	HADDOCK SOFTWARE INCLUDING A WATER SHELL IS ALSO USED FOR REFINEMENT	NMRView

NMR Ensemble Information
Conformer Selection Criteria	target function
Conformers Calculated Total Number	500
Conformers Submitted Total Number	25
Representative Model	1 (fewest violations)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	chemical shift assignment	NMRView		Johnson, One Moon Scientific
2	refinement	CYANA		Guntert, Mumenthaler and Wuthrich

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.